MARKET

AYLA

AYLA

Ayala Pharmaceuticals, Inc.
NASDAQ

Real-time Quotes | Nasdaq Last Sale

10.50
+0.05
+0.48%
Closed 16:00 04/13 EDT
OPEN
10.49
PREV CLOSE
10.45
HIGH
10.69
LOW
10.25
VOLUME
23.44K
TURNOVER
--
52 WEEK HIGH
28.68
52 WEEK LOW
8.62
MARKET CAP
138.28M
P/E (TTM)
-3.8610
1D
5D
1M
3M
1Y
5Y
Ayala Pharmaceuticals (AYLA) Receives a Buy from Oppenheimer
In a report released yesterday, Jay Olson from Oppenheimer maintained a Buy rating on Ayala Pharmaceuticals (AYLA), with a price target of $27.00. The
SmarterAnalyst · 03/26 00:45
Raymond James Keeps Their Buy Rating on Ayala Pharmaceuticals (AYLA)
Raymond James analyst Dane Leone reiterated a Buy rating on Ayala Pharmaceuticals (AYLA) today and set a price target of $24.00. The company's shares
SmarterAnalyst · 03/25 20:35
Ayala Pharmaceuticals EPS misses by $0.84, beats on revenue
Ayala Pharmaceuticals (AYLA): FY GAAP EPS of -$3.06 misses by $0.84.Revenue of $3.71M (+59.2% Y/Y) beats by $1.53M.Press Release
Seekingalpha · 03/25 13:03
Ayala Pharmaceuticals Reports Full Year 2020 Financial Results and Provides Business Update
- Completed $25 Million Strategic Financing; Extending Cash Runway into 2023 - Accelerated Development of AL102 Desmoid Tumor Program into Phase 2/3 Pivotal Trial - On Track to Report Multiple Milestones in 2021 Across Clinical-Stage Pipeline REHOVOT, Isra...
GlobeNewswire · 03/25 13:00
BRIEF-Ayala Pharmaceuticals Says Existing Cash Balance To Fund Operating Expenses And Capital Expenditure Requirements Into 2023
reuters.com · 03/25 12:26
Ayala Pharmaceuticals Q4 EPS $(0.73), Sales $1.00M
Ayala Pharmaceuticals (NASDAQ:AYLA) reported quarterly losses of $(0.73) per share. The company reported $1.00 million in sales this quarter.
Benzinga · 03/25 12:06
10-K: AYALA PHARMACEUTICALS, INC.
(EDGAR Online via COMTEX) -- Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations. You should read the following...
Edgar Online - (EDG = 10Q, 10K) · 03/24 20:07
Ayala Pharmaceuticals to Participate in Upcoming Virtual Investor Conferences
REHOVOT, Israel and WILMINGTON, Del., March 02, 2021 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (NASDAQ: AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare an...
GlobeNewswire · 03/02 13:00
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of AYLA. Analyze the recent business situations of Ayala Pharmaceuticals, Inc. through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average AYLA stock price target is 22.70 with a high estimate of 29.00 and a low estimate of 13.50.
EPS
Institutional Holdings
Institutions: 10
Institutional Holdings: 2.52M
% Owned: 19.10%
Shares Outstanding: 13.17M
TypeInstitutionsShares
Increased
2
102.54K
New
1
1.17K
Decreased
4
23.54K
Sold Out
1
459
  • Performance
  • Asset Allocation
  • Dividend History
No Data
No Data
No Data
About AYLA
Ayala Pharmaceuticals, Inc. is a clinical-stage oncology company. It is focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in genetically defined patient populations. The Company’s portfolio of product candidates include AL101 and AL102, which targets the aberrant activation of the Notch pathway with gamma secretase inhibitors. The Company’s lead product candidate, AL101, is being developed as a potent, selective, injectable small molecule gamma secretase inhibitor (GSI). It is evaluating AL101 as a monotherapy in an open-label Phase II clinical trial for the treatment of recurrent/metastatic adenoid cystic carcinoma (R/M ACC) for patients bearing Notch-activating mutations. The Company refer this trial as the ACCURACY trial. The Company uses advanced sequencing to identify patients with Notch-activating mutations, an approach that will enable it to target the patient population with cancers.

Webull offers kinds of Ayala Pharmaceuticals Inc stock information, including NASDAQ:AYLA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AYLA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading AYLA stock methods without spending real money on the virtual paper trading platform.